Search

everythinglearnresearchcommunity

for

Search:↓

Topical immunotherapy with DPCP led to some hair regrowth in most pediatric alopecia areata patients, especially those with milder cases and longer treatment.

Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.

Candida antigen is an effective and promising treatment for alopecia areata.

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

Children with frequent severe infections and low antibodies should be checked for immune deficiencies.

ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.

Transplant success has improved with better immunosuppressive drugs and donor matching.

A new test more accurately detects citrulline in hair follicles and pilomatrixomas.

Majocchi's granuloma can occur in kidney transplant patients on tacrolimus and can be treated with antifungal medication.

Poor response to topical immunotherapy in alopecia areata patients is linked to impaired cell responses.

New itaconate prodrugs improve its absorption and effectiveness for treating inflammation.

Contact immunotherapy can improve hair regrowth in alopecia areata patients.

The CUBIC protocol allows detailed 3D visualization of proteins in mouse skin biopsies.

Single-cell encapsulation shows promise for medical use but faces production challenges.

Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.

The document explains how the immune system reacts to organ transplants and the treatments used to prevent rejection.

AS101 reduces hair loss from chemotherapy.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

Monoclonal antibody B72.3 selectively reacts with certain dog tissues, mainly in the gastrointestinal and respiratory tracts.

Transplant patients on immunosuppressive medications have a higher risk of skin cancer, and managing this involves balancing medication with cancer risk.

Imiquimod shows promise as a non-invasive treatment for certain HPV-related lesions, but more research is needed to optimize its use.

The study found that a one-step antibody method is better than the LSAB method for accurately studying hair follicle structures without false positives.

Scalp cooling therapy helped over 80% of women keep at least half their hair during chemotherapy.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Imiquimod may be a better non-surgical treatment for cervical pre-cancer, but its effectiveness for vaginal pre-cancer is unclear, and it has some side effects.

The new protocol using Cellutome™ and RCM safely assesses wound healing in detail.